Crafts D C, Levin V A, Edwards M S, Pischer T L, Wilson C B
J Neurosurg. 1978 Oct;49(4):589-92. doi: 10.3171/jns.1978.49.4.0589.
Seventeen patients with recurrent medulloblastoma were treated with a combination of three drugs: procarbazine, CCNU, and vincristine (PCV). Tumor recurrence was documented at varying periods following surgery and radiotherapy. Among 16 evaluable patients, ten showed a response to PCV on the basis of subjective neurological improvement and a decrease in tumor size by radiological criteria. Five patients were designated as having stable disease on the basis of no change in neurological status and tumor size. One patient showed uninterrupted progression of disease. The median time to progression for all patients was 45 weeks. Significnat myelotoxicity, exacerbated by prior spinal irradiation, compromised therapy. After an initial response, it was often necessary to reduce the higher doses of CCNU and procarbazine that caused concomitant bone-marrow toxicity; as a consequence of the lowered doses, tumor progression was then frequently observed. The authors conclude that PCV is an effective form of palliative therapy for recurrent medulloblastoma.
17例复发性髓母细胞瘤患者接受了三种药物联合治疗：甲基苄肼、洛莫司汀和长春新碱（PCV）。肿瘤复发记录于手术和放疗后的不同时期。在16例可评估患者中，10例基于主观神经功能改善和影像学标准显示肿瘤大小减小而对PCV有反应。5例患者基于神经状态和肿瘤大小无变化被判定为疾病稳定。1例患者显示疾病持续进展。所有患者的中位进展时间为45周。显著的骨髓毒性因先前的脊髓照射而加重，影响了治疗。在初始反应后，通常有必要降低导致骨髓毒性的较高剂量的洛莫司汀和甲基苄肼；由于剂量降低，随后经常观察到肿瘤进展。作者得出结论，PCV是复发性髓母细胞瘤姑息治疗的一种有效形式。
